echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > The FDA has granted Bcl-2 inhibitor APG-2575 orphan drug eligibility for the treatment of chronic lymphocytic leukemia.

    The FDA has granted Bcl-2 inhibitor APG-2575 orphan drug eligibility for the treatment of chronic lymphocytic leukemia.

    • Last Update: 2020-09-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Chronic lymphocytic leukemia (CLL) is an adult leukemia characterized by the gradual accumulation of abnormal lymphocytes in exost blood, bone marrow, and lymphatic tissue.
    the American Cancer Society estimates that by 2020, about 4,060 people will die from the disease each year in the United States.
    Biotech company Aachen Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has awarded the new Bcl-2 inhibitor APG-2575 orphan drug title (ODD) for the treatment of chronic lymphocytic leukemia (CLL).
    APG-2575 is a new oral Bcl-2 selective inhibitor developed by Asaan Pharmaceuticals.
    APG-2575 is able to selectively block Bcl-2 to restore normal apoptosis in cancer cells, thereby treating various blood system malignancies.
    APG-2575 is one of the few Bcl-2 selective inhibitors in the world and the first Bcl-2 selective inhibitor to be developed in China, and has entered clinical trials in China.
    APG-2575 as a single drug or in a combined treatment with other therapeutic drugs relapsed/refractic CLL/SLL (small lymphocyte lymphoma) has been conducted in China, Australia and the United States in a number of IB / II clinical studies.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.